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Toxoplasma gondii is an obligate intracellular protozoan parasite classiﬁed in the phylum Apicomplexa, which includes numerous
notable human and animal pathogens (Plasmodium species, Cryptosporidium species, Neospora caninum, etc.). The invasive
stages of apicomplexans are characterized by the presence of an apical complex composed of specialized cytoskeletal and
secretory organelles, including rhoptries. Rhoptries, unique apical secretory organelles shared exclusively by all apicomplexan
parasites, are known to be involved in an active parasite’s penetration into the host cell associated with the biogenesis of speciﬁc
intracellular compartment, parasitophorous vacuole in which the parasite multiplies intensively, avoiding intracellular killing.
Due to the key biological role of rhoptries, rhoptry proteins have recently become vaccine candidates for the prevention of several
parasitoses, toxoplasmosis among them. The article presents current data on T. gondii rhoptries biology and new approaches to
the development of eﬀective vaccines against toxoplasmosis using rhoptry antigens.
Copyright © 2008 Henryka Dlugonska. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Toxoplasma gondii is arguably the most successful protozoan
parasite on earth. It infects humans and many species of
endothermic animals with a great infection rate, achieving
nearly 100% in some local populations [1]. The course,
symptoms, and consequences of T. gondii infection depend
strongly on the virulence and inoculum size of the parasite
and the genetic background and immune status of the
infectedhost.Ingeneral,mostpostnatalcasesoftoxoplasmo-
sis are mild and subclinical, with lifelong persistence of the
parasite in the host. However, in immunosuppressed beings,
both primary infection and reactivation of chronic infection
could occur very serious, causing even death. Primary
infection acquired during pregnancy can lead to an abor-
tion and neonatal malformations. Unfortunately, despite
many eﬀorts there are no satisfactory immunoprevention
methods against toxoplasmosis. The only accepted vaccine
against toxoplasmosis (Toxovax, Ovilis Toxovac) contains
live tachyzoites of incomplete nonpersistent S48 strain and
is used to prevent congenital toxoplasmosis in sheep. The
vaccine causes a decrease in abortion cases frequency but not
complete eradication of the parasite [2].
2. TOXOPLASMA GONDII: OBLIGATE INTRACELLULAR
APICOMPLEXAN PARASITE
Successful parasitism by T. gondii is based on its ability
to form within the host cell a replication permissive
niche—parasitophorous vacuole (PV). This growing niche
is delimited from the host cell cytoplasm by PV membrane
(PVM), a unique and dynamic “organelle” found only in
infected cells which prevents T. gondii degradation by the
host cell endocytic machinery and enables parasite’s intra-
cellular propagation. Unique to the apicomplexan protozoa
including Toxoplasma gondii are also three types of electro-
densesecretoryorganelles:micronemes,rhoptries,anddense
granules, carrying their characteristic proteins: MICs, RONs,
R O P s ,a n dG R A s ,r e s p e c t i v e l y;s e eTable 1.H o s tc e l li n v a s i o n
is mediated by the sequential secretion of the contents
of all three organelles, which are exocytosed at the apical
region when the parasite invades the host cell. The processes,2 Journal of Biomedicine and Biotechnology
Table 1: The participation of secretory organelles proteins in the invasion of the host cell by protozoan Toxoplasma gondii;P V :
parasitophorous vacuole, MICs: micronemes proteins, TgAMA1: T. gondii apical membrane antigen 1, RONs: rhoptry neck proteins, ROPs:
rhoptry proteins, GRAs: dense granule proteins.




Biogenesis of moving junction, PV and its association with
host mitochondria and endoplasmic reticulum
Rhoptries/transient
RONs, ROPs
Formation of the speciﬁc architecture and function of PV Dense granules/continuous
GRAs
critical in the establishment of a productive infection, are
highly regulated at possibly two levels: physical separation
of exocytosis sites in the parasite’s plasma membrane and
diﬀerenttriggermechanisms[3,4].Micronemesareinvolved
in the attachment and penetration of T. gondii, while rhop-
triesarerequiredforcreatingatransientenigmaticstructure,
moving junction and then the establishment of PV. Host
cell entry of the parasite is completed in 15–20 seconds
[5, 6]. Dense granules secrete proteins throughout most of
the parasite stages. The secretion process coincides with the
formation of intravacuolar network and continues during
the intracellular residence of T. gondii [3, 4].
3. RHOPTRIES AND RHOPTRIES PROTEINS
Unlikemostsecretoryandlysosomalgranulesinmammalian
cells, which are of a semispheroidal shape, the mature rhop-
tries are club shaped with a bulbous base and an extended
duct (neck), connected to the extreme apical pole of the
parasite.Therhoptriesinthenumberof8–12percelloccupy
10–30% of the total cell volume. They are the only known
acidiﬁed organelles in T. gondii; pH of immature rhoptries is
3.5–5.5andofmaturerhoptriesis5.0–7.0[7].Mostprobably
each mature rhoptry originates from a separate immature
rhoptry [8].
Current ﬁndings suggest that rhoptries are most anal-
ogous to secretory lysosomal granules because they receive
materialfrombothbiosyntheticandendocyticcellpathways.
In the exit site of endoplasmic reticulum, the rhoptry
proteins (in a form of proproteins) are loaded into coated
vesicles and then travel to the Golgi apparatus where they
are sorted to an immature rhoptry using the speciﬁc sorting
signals [9]. Both tyrosine-based and dileucine sorting motifs
were detected within cytoplasmic tails of the predominant
ROP2 family proteins [10]. Proproteins undergo proteolytic
cleavage of an N-terminal prodomain, which occurs in
post-Golgi compartment, probably in immature rhoptries
[11]. In contrast to all known prominent ROP2 family
members, a new described ROP5 protein is not processed
during traﬃcking but is synthesized in the mature form [12].
Some rhoptry cargo is delivered by endosomal pathway via
multivesicular body and immature rhoptry [9]. Immature
rhoptries evolve into mature rhoptries characterized by
speciﬁc morphology and subcompartmentalization of their
contents: ROP proteins are located in the bulb body whereas
RONs in the neck of the rhoptry [13].
A proteomic analysis revealed over 30 rhoptry proteins,
all localized in the contents of the rhoptries, although
manyoftheidentiﬁedproteinshaveputativetransmembrane
domains [13]. As shown for ROP2, a prototype protein
of ROP2 protein family, apart from an N-terminal signal
sequence, the molecule is characterized by the high abun-
dance of charged amino acids and proline residues, N-
terminal arginine-rich stretches and hydrophobic sequence
in C-terminus considered as transmembrane domain [14,
15]. The ROP2 protein was shown to be inserted in PVM
during the invasion of a host cell and its N-terminal domain
is exposed to host cytosol [14] mediating the association
of parasitophorous vacuole with host cell mitochondria
[14, 16]. Targeted depletion of ROP2 resulted in multiple
eﬀects, such as: (i) impairments of rhoptry biogenesis and
cytokinesis, (ii) reduction in the association of host cell
mitochondria with PVM of the parasite, and a reduced
sterol uptake from the host cell, and (iii) reduced capacity
to invade and replicate in vitro in human ﬁbroblasts and
attenuation of virulence in mice [17]. Besides, anti-ROP2
antibodies caused a decrease in the invasion ability of T.
gondii RH tachyzoites in vitro [18]. The observed eﬀects of
ROP2 depletion or inactivation and simultaneous synthesis
of several related proteins (ROP2 family) suggest that they
serve crucial biological functions. All members of the ROP2
family contain a protein kinase-like domain but only some
of them are catalytically active [15]. The exocytosis of
rhoptry contents coincides with the formation of PV but
the biological trigger of rhoptry secretion has not been
identiﬁed. Mobilization of intracellular Ca2+ by ionophores
triggers the discharge of micronemes but not rhoptries and
densegranules[19].Incontrasttoothersecretoryorganelles,
rhoptry proteins and lipids are exocytosed through the duct,
whereas delimiting membrane is retained in the cell and
the rhoptry is transiently empty. Secreted rhoptry proteins
are subsequently discharged into nascent parasitophorous
vacuole and localized in its membrane [14, 20].
As mentioned earlier, certain rhoptry proteins are prefer-
entially localized in the neck of the rhoptry. During invasion,
RON4 relocalizes at the moving junction and participatesHenryka Dlugonska 3
in the formation of this short living and very enigmatic
structure between the host cell and the parasite, sliding over
the parasite as it invades [21]. RON4, RON2, and RON5
(Ts4705) form protein trio that associates with adhesion
microneme protein TgAMA1 (T. gondii apical membrane
protein 1) forming an unusual complex derived from two
distinctsecretoryorganelles:rhoptriesandmicronemes[22].
Moving junction functions as a molecular sieve for the quick
selective sorting of parasite surface components (like RONs-
TgAMA1 complex mentioned above) as well as surface
proteinsofthehostcell.Becauseoftheexclusionofmosthost
cellmembraneproteins,developingparasitophorousvacuole
is not recognized by the host cell fusogenic machinery
enabling the vigorous parasite proliferation in this safe
intracellular compartment [5, 23].
4. VIRULENCE OF T. GONDII AND NEW
DESCRIBED RHOPTRY ANTIGENS AS MAJOR
VIRULENCE COMPONENTS
Despite the very high genetic homology achieving ∼98%,
T. gondii strains express dramatic diﬀerences in many
phenotype aspects, including virulence. The majority of
T. gondii isolates from Europe and North America belong
to three clonal lines (types) signiﬁcantly diﬀering in their
virulence, which has been well characterized in the mouse
model. Type I isolates have an LD100 of a single organism
and lead to rapid death of the infected mice (6–10 days),
whereas types II and III (called nonvirulent or avirulent)
typically have LD100 of ≥103 organisms; mice which survive
acutephaseoftoxoplasmosisremainchronicallyinfectedand
highly seropositive [24].
Dramatic diﬀerences in acute virulence between three
major types of T. gondii enabled the mapping of virulence
genes by an analysis of F1 progeny from genetic crosses
between three toxoplasma types, using an experimental
mouse model to test virulence. The method applied to types
I × III recombinants revealed ﬁrst two closely adjacent viru-
lence loci on parasite chromosome VIIa and then single gene
encoding ROP18 protein as a major virulence component.
Type III and type I alleles of ROP18 diﬀered signiﬁcantly in
nucleotide sequence and expression level. The contribution
of ROP18 to virulence was conﬁrmed by the transfection
of the virulent ROP18 allele into nonpathogenic type III
parasite strain. The obtained transformants showed an
increased growth rate in vitro and an enhanced mortality by
4to5logsinCD1mice,ascomparedtowildnontransformed
strain [25]. Saeij et al. [26] mapped virulence in F1 progeny
derived from crosses between type II and type III strains.
Five virulence loci were identiﬁed, and two of them coded
rhoptry proteins: ROP18 and ROP16, both hypervariable
protein kinases that are responsible for the high virulence
of certain strains of the parasite. Contrary to ROP2 and
several other members of this family that lost detectable
kinase activity [15] and retained “molecular fossils” [27],
newly described rhoptry proteins ROP16 and ROP18 are
true kinases, the substrates of which are unknown. Both
kinases presumably disrupt some signaling processes and
alter intracellular environment in a way that favors parasite
growth. The work of El Hajj et al. [28]b r o u g h tm a n y
interesting data on ROP18. The protein showed a very strong
tropism to PVM and during the invasion it was translocated
from rhoptry to PVM. The mature recombinant ROP18
was able to phosphorylate two as yet unknown parasite’s
(but not host’s) proteins, a major one of 70kDa and a
minor one of 68kDa. The overexpression of ROP18 protein
promoted dramatically parasite’s proliferation, whereas the
mutation (D394A) in ROP18 molecule resulted in the loss
of both the enzyme activity and accelerated growth. In
contrast to ROP18, the second recently described rhoptry
protein, ROP16 is translocated to the host cell nucleus like
phosphatase 2C [29], subverts STAT3/6 signaling, and, in
consequence, IL-12 production in infected host cells. Allele
shared by types I and III of the parasite induce prolonged
phosphorylation of STAT3 (STAT3-PO4) which results in a
much lower level of IL-12 secretion, as compared to type II
allele [30]. The observed type-speciﬁc eﬀects show the key
role of ROP kinases in T. gondii virulence and could explain
diﬀerentdiseaseoutcomesseenwithtypeI,II,andIIIstrains.
The role of ROPs in virulence suggests that they could be
promising vaccine candidates against toxoplasmosis.
In contrast to ROP18 and ROP16, another novel rhoptry
protein, bradyzoite rhoptry protein 1 (BRP1), is expressed
in bradyzoites but absent from tachyzoites. Bradyzoites are
a low-replicating, inactive developmental stage, sequestered
in tissue cysts, which are a typical marker of chronic
toxoplasmosis. The biological function of BRP1 is not
deﬁned yet. This protein does not play an essential role in the
development of the bradyzoite stage, brain cyst formation,
and oral infection of new hosts [31].
5. IMMUNOPROPHYLAXIS OF TOXOPLASMOSIS
As mentioned earlier, the only vaccine against toxoplas-
mosis has been licensed for use in sheep in Europe and
New Zealand [2]. This conventional vaccine contains live
attenuated tachyzoites of the nonpersistent T. gondii S48
strain and it cannot be considered for an application in
humans because of the risk of reverting to tissue cyst
formation. From both humanitarian and economic points
of views, an eﬀective anti-T. gondii vaccine(s) for humans
and animals is still strongly desired. Taking into account
the main sources and transmission routes of T. gondii,h o s t
groups of a particularly high infection risk and consequences
of congenital infection, as well as postnatal infections in
immunocompromised individuals, targets for vaccination
strategy should include (i) preventing tissue cyst formation
in consumption animals (to avoid parasite transmission to
humans and animals) and in people (to protect against
reactivation of infection in immunosuppression state of
persistently infected individuals), (ii) reducing oocyst shed-
ding in cats (to limit environmental contamination and
infection risk for all intermediate hosts), and (iii) preventing
development of parasitemia in pregnant women and farm
livestock (to avoid transplacental transmission to the fetus
and congenital toxoplasmosis) [32].
VaccinecandidatesshouldinduceprotectivecellularTH1
and humoral responses as well, both at the level of intestinal4 Journal of Biomedicine and Biotechnology
mucosa(local)andwholeorganism(systemic).Manystudies
have shown that protective immunity to T. gondii is charac-
terized by the development of cell-mediated immunity dom-
inated by the production of IFN-γ b yTl y m p h o c y t e s( aT H 1
type response). Whereas immune CD8+ lymphocytes are
cytotoxic for T. gondii-infectedhostcells,CD4+lymphocytes
exert their protective activity primarily by the production of
manyproinﬂammatorycytokines(IFN-γ,TNF-α,IL-12)and
providing growth factor, IL-2. Speciﬁc antibodies limit mul-
tiplication of T. gondii by killing of extracellular tachyzoites,
either by activating complement, or opsonizing the parasites
for phagocytosis and next killing by macrophages [33]. The
major challenge in novel vaccine construction is a selection
of relevant T. gondii antigens and then their presentation to
host immune system in an appropriate manner to induce
strong and long-lasting protective immunity. Because of
the complex life cycle of the parasite, the expression of
numerous common and stage-dependent antigenic epitopes
andhost-dependentimmuneresponses,thevaccinationwith
multiantigenpreparationcomprisingantigensfromdiﬀerent
l i f ec y c l es t a g e si sl i k e l yt ob em o r ee ﬃcacious than with
a single antigen. Previous and current vaccine approaches
focus not only on classic formulations (live attenuated or
mutant T. gondii strains) [2, 34, 35]b u tm o r eo f t e no n
the deﬁned subcellular components of the parasite such
as biosynthetic (recombinant) antigens [36] and naked T.
gondii DNA [37]o rR N A[ 38]. Nonpathogenic recombinant
microorganisms with the expression of immunoprotective
antigens of T. gondii (live vector vaccines) [39] and synthetic
peptides have also been tested as interesting antitoxoplasmic
vaccine alternatives [40]. These new generation subunit
vaccines require an addition of potent adjuvants enhancing
the intensity of the immune response and inducing the
desired TH1 proﬁle. Several new compounds, for instance
unmetylated CpG nucleotides, present satisfactory adjuvant
TH1 activity [41].
6. RHOPTRY ANTIGENS AS A POTENTIAL VACCINE
AGAINST TOXOPLASMOSIS
Most of the current vaccine candidates for T. gondii and
other apicomplexa are either surface or secreted antigens
that appear to be essential for the invasion process, rhoptry
proteins among them. Until now several rhoptry proteins
of T. gondii have been tested as vaccines. Garcia et al. [42]
used crude native rhoptry antigens incorporated in the
immunostimulating complexes (ISCOMs) to protect pigs
against an infection with oocysts of T. gondii VEG strain (of
type III). Two-fold subcutaneous immunization procedure
led to a partial protection against cysts formation in muscles
andbrainduringchronicinfection(asconﬁrmedbybioassay
in mice) but it was not protective against acute infection,
probably because of the lack of intestinal immunity after
subcutaneous immunization. Taking into account epidemi-
ological role of cats as an important source of T. gondii
dissemination by shedding millions of oocysts in feces, the
authors tested the same antigen material in domestic cats
[43]. The cats were immunized intranasally three times (0,
21, 42 day) with crude rhoptry proteins adjuvanted with
Quil-A and then challenged with tissue cysts of the T. gondii
VEG strain. This vaccination procedure resulted in a partial
protection only—two from three immunized cats did not
shed oocysts.
Till now vaccine trials with individual ROPs of T. gondii
have mostly focused on the ROP2 antigen, prominent mem-
ber of ROP2 protein family. In majority, the experiments
were performed with DNA vaccines which are believed to
elicitapredominantTH1response.Vercammen[44]showed
that the immunization with ROP2 gene protected mice
against lethal challenge with a highly virulent RH strain,
but the observed protection was mouse strain dependent—
inbred C3H mice were protected, whereas C57BL/6 and
BALB/c were not.
Similar results were obtained by Leyva et al. [45]i nm i c e
of three inbred strains (CBA/J, C57BL/6, and BALB/c),
vaccinated with plasmid encoding antigen ROP2. The mice
did not resist a challenge with RH strain but the protection
was achieved by vaccination with live tachyzoites of the
T. gondii nonpersistent thermosensitive ts-4 strain. In the
mice immunized with ROP2-plasmid, a mixed TH1/TH2
immune proﬁle instead of a desirable TH1 proﬁle and a
signiﬁcant variability in the response between individual
mice was observed. Using similar vaccine material, that is,
ROP2-plasmid, Wei et al. [46] reported both a high immune
response and signiﬁcant immunoprotection against a lethal
dose of T. gondii RH strain in BALB/c mice.
Recently, live nonpathogenic microbes (viruses or bacte-
ria)wereusedasvectorsofselectedROPgenes.Recombinant
vaccinia virus carrying ROP2 gene induced in mice a speciﬁc
humoral response very similar, in intensity and proﬁle, to
the thermosensitive ts-4 strain of T. gondii. Because the ts-
4s t r a i na sv a c c i n ew a sa b l et of u l l yp r o t e c tm i c ea g a i n s tt h e
challenge with the highly virulent RH strain, the authors
conclude by analogy that ROP2-vaccinia virus could be
equally eﬀective in toxoplasmosis immunoprotection [47].
Mishima et al. [18] obtained recombinant feline herpesvirus
1 (FHV1) encoding ROP2 and evaluated its ability to induce
antitoxoplasmic activity and protective immune responses.
Antisera of ROP2-FHV1-immunized cats reduced signiﬁ-
cantly the invasion capacity of T. gondii RH tachyzoites in
vitro. The number of parasites in the brains of immunized
cats lowered, however oocyst shedding intensity was not
reduced. Recently, Wang et al. [48] tested the eﬃcacy of
recombinant Mycobacterium bovis BCG expressing ROP2
gene as a vaccine, using mouse experimental toxoplasmosis
model. BCG, widely applied in immunoprophylaxis of
tuberculosis, is a particularly attractive vector for delivering
heterologous antigens because mycobacteria elicit TH1-
mediated immune response without an additional adjuvant
[49]. Vaccine ROP2-BCG induced strong speciﬁc humoral
and cellular (IL-2 and IFN-γ in supernatants of splenocytes
cell cultures) immunity. A signiﬁcant delay in mortality after
the infection with the highly virulent RH strain was also
observed [48].
The use of recombinant ROP2 antigen, instead of
ROP2-plasmid, revealed again in mouse experimental model
that the protective activity of ROP2 protein is mouse
strain-dependent; ROP2 vaccination resulted in the partialHenryka Dlugonska 5
protection (decrease in tissue cyst burden) only in C3H mice
but not C57BL/6 mice [50]. The eﬃcacy of ROP2 protein
vaccine signiﬁcantly increased by including new immunos-
timulatory components, Leishmania infantum heat shock
protein83(Hsp83)fusedwiththeROP2[51].Immunization
withthisfusionproteinelicitedapredominantTH1response
in all mouse strains used (BALB/c, C57Bl/6, and C3H),
whereas ROP2 alone or in mixture with Hsp83 induced a
mixed TH1/TH2 proﬁle.
Multiple endogenous and exogenous parameters can
inﬂuence the type and intensity of vaccine-induced immune
response. The results obtained on inbred mouse strains
proved that the protection induced by ROP2 and other
vaccine antigens of T. gondii is strongly dependent on the
host genetic background [43, 50, 52]. In relation to the
vaccine itself, the composition seems a very important factor
in the context of both selected ROP antigens and adjuvants
used. In the light of our current knowledge on rhoptry
antigens, ROP18 protein, described recently as a major com-
ponent of pathogenicity of T. gondii,s e e m sav e r yp r o m i s i n g
candidate for a vaccine, as a single antigen or, more possibly,
accompanied by other T. gondii antigens because many
previous studies showed greater eﬀectiveness of combined
than single-antigen vaccines. However, the usefulness of
ROP18 as a vaccine antigen for toxoplasmosis needs to
be experimentally conﬁrmed, especially in relation to the
polymorphism of this protein. Whether protection across
T. gondii species could be achieved with that polymorphic
antigen remains an open question.
The advantages of combined vaccines as compared
to single-antigen vaccines were recently emphasized by
Zhang et al. [53] who constructed a multiantigenic DNA
vaccine consisting of plasmid encoding both ROP2 and
surface antigen 1 (SAG1) antigens and inoculated it to
BALB/c mice with or without plasmid encoding murine
IL-12. Multiantigenic (cocktail) vaccine elicited stronger
antibody and cellular responses than single-gene vaccines
and, additionally, coimmunization with IL-12 gene sig-
niﬁcantly enhanced the intensity of immune responses.
The most immunostimulating vaccine, pSAG1+ROP2+pIL-
12, delayed about three times the survival time of mice
after a lethal challenge with RH tachyzoites. As found by
Guo et al. [54] another genetic adjuvant, plasmid carrying
IFN-γ, revealed also a potent stimulatory activity, enhancing
the cellular immune response induced in mice by ROP1-
plasmid.
In summary, all the above presented experimental vacci-
nation strategies with ROP antigens still remain suboptimal
but the vaccination results appear promising and therefore
future research on ROP vaccine seems rational.
7. CONCLUDING REMARKS
Toxoplasmosis, widely dispersed in the populations of
humans and endothermic animals all over the world, is
a serious problem of human and veterinary medicine in
the case of immunocompromised individuals (fetuses, AIDS
patients, etc.). The consequences of primary infection in
pregnant females and the possibility of reactivation of latent
infection in immunodepressed individuals cause that both
immunoprophylactic and immunotherapeutic vaccines are
needed. Natural infection with Toxoplasma leads to strong,
lifelong nonsterile protective immunity. The persistence
of the memory T lymphocytes, stimulated by the regular
rupture of T. gondii tissue cysts or by recurrent contact with
infected food, prevents a reinfection in most individuals
[33]. The eﬀective and safe vaccine should mimic the
immune response observed in natural infections and protect
the hosts against T. gondii infection, however without the
potential risk of tissue cyst generation in intermediate hosts
and development of oocysts in cats, associated with the
vaccination using live attenuated or incomplete parasite
strains. In this context, for T. gondii ROP antigens as key
molecules in biogenesis of parasite intracellular niche in the
host cells and their association with host organelles, major
virulence factors showing satisfactory immunogenicity [55]
seem particularly valuable vaccine candidates for toxoplas-
mosis prophylactic approaches but their vaccine potential
needs experimental conﬁrmation. It is worth mentioning
that rhoptry proteins are also vaccine candidates in other
apicomplexa, including rhoptry-associated protein 1 (RAP1)
and RAP2 proteins of Plasmodium falciparum [56]. Several
rhoptry proteins are polymorphic, with T and B epitopes
that are conserved among strains but not across species and
over species, as found for instance for Plasmodium [57]
and Eimeria [58]. The question, if it would be possible to
construct universal anti-T. gondii vaccine, independent of
the host and vaccination target, remains open. The results
of the studies on ROP-vaccine presented in this paper are
promising and could be a good starting point to develop an
eﬀectivevaccinenotonlyforthepreventionoftoxoplasmosis
but also other parasitoses caused by apicomplexan protozoa.
Recent advances in bioinformatics and experimental tools
will make the selection of vaccine candidates easier.
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